Janssen prevails in Darzalex dispute with Genmab

8 April 2022
law-trial-judge-large-1-

Danish firm Genmab (CPH: GMAB) was trading nearly 4% lower on Friday afternoon after the company lost out in a dispute with the Johnson & Johnson (NYSE: JNJ) subsidiary Janssen.

Genmab announced that there had been an award in the binding arbitration of two matters arising under its license agreement with Janssen relating to daratumumab, a multiple myeloma drug branded as Darzalex that had global sales exceeding $6 billion last year.

The arbitral tribunal issued an award on Thursday, deciding both issues in favor of Janssen, although Genmab has the time-limited right to appeal and is currently considering its options.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology